MDM2 and neoplasm: RPL23 has been reported to participate in a typical signaling pathway in malignancies, wherein RPL23 blocks the inhibitory function of the oncoprotein murine double minute 2 (MDM2) to target and ubiquitinate p53 via the RP‐MDM2‐p53 axis, further controlling tumor cell growth.63, 64, 65, 66